CN104995300B - Rna活性和血管通透性的调节 - Google Patents

Rna活性和血管通透性的调节 Download PDF

Info

Publication number
CN104995300B
CN104995300B CN201380061417.2A CN201380061417A CN104995300B CN 104995300 B CN104995300 B CN 104995300B CN 201380061417 A CN201380061417 A CN 201380061417A CN 104995300 B CN104995300 B CN 104995300B
Authority
CN
China
Prior art keywords
oligonucleotides
seq
mir
bases
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380061417.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104995300A (zh
Inventor
詹尼弗·甘布尔
马修·瓦达斯
索尔莱夫·默勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centenary Institute of Cancer Medicine and Cell Biology
The University of Sydney
MIRRX THERAPEUTICS AS
Original Assignee
Centenary Institute of Cancer Medicine and Cell Biology
The University of Sydney
MIRRX THERAPEUTICS AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904297A external-priority patent/AU2012904297A0/en
Application filed by Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, MIRRX THERAPEUTICS AS filed Critical Centenary Institute of Cancer Medicine and Cell Biology
Publication of CN104995300A publication Critical patent/CN104995300A/zh
Application granted granted Critical
Publication of CN104995300B publication Critical patent/CN104995300B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
CN201380061417.2A 2012-10-02 2013-10-02 Rna活性和血管通透性的调节 Active CN104995300B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2012904297 2012-10-02
AU2012904297A AU2012904297A0 (en) 2012-10-02 Modulation of RNA activity and vascular permeability
AU2012904365A AU2012904365A0 (en) 2012-10-05 Modulation of RNA activity and vascular permeability
AU2012904365 2012-10-05
PCT/AU2013/001129 WO2014053014A1 (en) 2012-10-02 2013-10-02 Modulation of rna activity and vascular permeability

Publications (2)

Publication Number Publication Date
CN104995300A CN104995300A (zh) 2015-10-21
CN104995300B true CN104995300B (zh) 2018-07-17

Family

ID=50434322

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380061417.2A Active CN104995300B (zh) 2012-10-02 2013-10-02 Rna活性和血管通透性的调节

Country Status (7)

Country Link
US (1) US9879255B2 (cg-RX-API-DMAC10.html)
EP (1) EP2904102B1 (cg-RX-API-DMAC10.html)
JP (1) JP6430945B2 (cg-RX-API-DMAC10.html)
CN (1) CN104995300B (cg-RX-API-DMAC10.html)
AU (1) AU2013327393B2 (cg-RX-API-DMAC10.html)
CA (1) CA2886745A1 (cg-RX-API-DMAC10.html)
WO (1) WO2014053014A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9879255B2 (en) 2012-10-02 2018-01-30 University Of Newcastle Upon Tyne Modulation of RNA activity and vascular permeability
EP3331535A4 (en) * 2015-08-05 2019-03-13 Centenary Institute Of Cancer Medicine And Cell Biology METHOD FOR TREATING TUMORS
CN105861728B (zh) * 2016-06-12 2024-11-19 上海市第十人民医院 循环miRNA作为年龄相关黄斑变性诊断标志物中的应用
WO2025102119A1 (en) * 2023-11-16 2025-05-22 Centenary Institute Of Cancer Medicine And Cell Biology Improvement of blood brain barrier integrity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641440A (zh) * 2006-11-23 2010-02-03 米尔克斯治疗有限责任公司 用于调节靶rna活性的寡核苷酸
CN101821390A (zh) * 2007-06-14 2010-09-01 米尔克斯治疗有限责任公司 用于调节靶rna活性的寡核苷酸
WO2010139026A1 (en) * 2009-06-05 2010-12-09 Centenary Institute Of Cancer Medicine And Cell Biology Therapeutic and diagnostic molecules
US20110065778A1 (en) * 2002-02-20 2011-03-17 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Muscarinic Colinergic Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000103736A (ja) * 1998-07-31 2000-04-11 Takeda Chem Ind Ltd 血管透過性亢進抑制剤
JP2000143536A (ja) * 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 抗浮腫剤
EP1900374B1 (en) * 2005-06-16 2014-03-12 Takayuki Shindo Angiogenetic agent containing adrenomedulin as the active ingredient
AU2014250708B2 (en) 2006-11-23 2016-11-10 Guangdong Maijinjia Biotechnology Co., Ltd Oligonucleotides for modulating target RNA activity
AU2007323469B2 (en) 2006-11-23 2014-07-24 Guangdong Maijinjia Biotechnology Co., Ltd Oligonucleotides for modulating target RNA activity
SG2014008171A (en) * 2009-06-22 2014-04-28 Ampio Pharmaceuticals Inc Method for treatment of diseases
WO2011117353A1 (en) 2010-03-24 2011-09-29 Mirrx Therapeutics A/S Bivalent antisense oligonucleotides
US9145557B2 (en) 2010-11-23 2015-09-29 Mirrx Therapeutics A/S Oligonucleotides for modulation of target RNA activity
CN104955950B (zh) 2012-09-26 2019-04-26 米尔克斯治疗学公司 具有改善的脱靶特征谱的寡核苷酸
US9879255B2 (en) 2012-10-02 2018-01-30 University Of Newcastle Upon Tyne Modulation of RNA activity and vascular permeability
CN104902901A (zh) 2012-10-19 2015-09-09 株式会社棱镜制药 使用cbp/连环蛋白的抑制剂治疗过度增殖性和癌前皮肤病

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065778A1 (en) * 2002-02-20 2011-03-17 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Muscarinic Colinergic Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA)
CN101641440A (zh) * 2006-11-23 2010-02-03 米尔克斯治疗有限责任公司 用于调节靶rna活性的寡核苷酸
CN101821390A (zh) * 2007-06-14 2010-09-01 米尔克斯治疗有限责任公司 用于调节靶rna活性的寡核苷酸
WO2010139026A1 (en) * 2009-06-05 2010-12-09 Centenary Institute Of Cancer Medicine And Cell Biology Therapeutic and diagnostic molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The Oncogenic microRNA-27a Targets Genes That Regulate Specificity Protein Transcription Factors and the G2-M Checkpoint in MDA-MB-231 Breast Cancer Cells;Susanne U. Mertens-Talcott 等;《Cancer Res》;20071215;第67卷(第2期);第2043-2049页 *
血清microRNAs在胃肠道疾病中的意义;熊青 等;《世界华人消化杂志》;20120808;第20卷(第22期);第11001-11011页 *

Also Published As

Publication number Publication date
WO2014053014A1 (en) 2014-04-10
EP2904102B1 (en) 2018-11-21
AU2013327393A1 (en) 2015-05-21
US9879255B2 (en) 2018-01-30
JP6430945B2 (ja) 2018-11-28
EP2904102A1 (en) 2015-08-12
AU2013327393B2 (en) 2019-07-18
CA2886745A1 (en) 2014-04-10
CN104995300A (zh) 2015-10-21
EP2904102A4 (en) 2016-07-06
JP2015533085A (ja) 2015-11-19
US20160040160A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
US20250270555A1 (en) Organic compositions to treat beta-catenin-related diseases
EP3210611B1 (en) Methods of treating vascular inflammatory disorders
JP2014509512A (ja) オリゴマーの増強された体内分布
KR20240036132A (ko) 대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법
KR102246814B1 (ko) 치료용 올리고뉴클레오타이드
US9322015B2 (en) Methods of using microRNA-26a to promote angiogenesis
EP3329004B1 (en) Therapeutic oligonucleotides
US9879255B2 (en) Modulation of RNA activity and vascular permeability
JP2012528797A (ja) 治療用及び診断用分子
US11903960B2 (en) Treatment methods for fibrosis targeting SMOC2
US20230287427A1 (en) Inhibition of lncExACT1 to Treat Heart Disease
KR101783444B1 (ko) miR-33-5p 를 이용한 뇌신경세포 보호 물질 스크리닝 방법
US10260067B2 (en) Enhancing dermal wound healing by downregulating microRNA-26a
CA3054284C (en) Treatment methods for fibrosis targeting smoc2
HK40122379A (en) Treatment methods for fibrosis targeting smoc2
CN116801916A (zh) 包含miR 145抑制剂作为有效成分的用于治疗心肌梗塞的组合物
HK40002857A (en) Treatment methods for fibrosis targeting smoc2
HK40002857B (en) Treatment methods for fibrosis targeting smoc2

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant